XRAY XRAY
Company Profile ↓Company Overview
XRAY (XRAY) is a publicly traded company listed on with a market capitalization of $3.54B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Net profit has compounded at 12.4% per year over the last five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $3.68B (-3.0% YoY); net profit $-598.00M.
- Trailing 12 Months Year-on-year growth — revenue -3.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -2.1%, profit CAGR 12.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -2.10% |
| 1 Year: | -2.98% |
Compounded Profit Growth
| 5 Years: | 12.35% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -3.91% |
| 6 Months: | +8.96% |
| 3 Months: | +13.79% |
| 1 Month: | +20.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.81 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 12.4% over 5 years.
- Generates positive free cash flow.
CONS
- Revenue declined at -2.1% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 879.00M | 936.00M | 904.00M | 961.00M | 880.00M |
| Cost of Revenue | - | 413.00M | 446.00M | 463.00M | 518.00M | 453.00M |
| Gross Profit | - | 466.00M | 490.00M | 441.00M | 443.00M | 427.00M |
| Operating Expenses | - | 396.00M | 380.00M | 395.00M | 418.00M | 397.00M |
| Operating Income | - | 70.00M | 110.00M | 46.00M | 25.00M | 30.00M |
| EBITDA | - | 142.00M | -41.00M | -115.00M | -32.00M | 61.00M |
| Interest Expense | - | 19.00M | 24.00M | 23.00M | 22.00M | 24.00M |
| Pretax Income | - | 44.00M | -153.00M | -230.00M | -147.00M | -42.00M |
| Tax Provision | - | 25.00M | -109.00M | 198.00M | -2.00M | -32.00M |
| Net Income | - | 20.00M | -45.00M | -427.00M | -146.00M | -10.00M |
| Diluted EPS | - | 0.10 | -0.22 | -2.14 | -0.74 | -0.05 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 3.92B | 3.96B | 3.79B | 3.68B |
| Cost of Revenue | - | 1.79B | 1.88B | 1.83B | 1.84B |
| Gross Profit | - | 2.13B | 2.09B | 1.96B | 1.84B |
| Operating Expenses | - | 1.76B | 1.80B | 1.77B | 1.59B |
| Operating Income | - | 364.00M | 289.00M | 188.00M | 252.00M |
| EBITDA | - | -662.00M | 249.00M | -518.00M | -46.00M |
| Interest Expense | - | 65.00M | 81.00M | 69.00M | 88.00M |
| Pretax Income | - | -1.05B | -175.00M | -936.00M | -486.00M |
| Tax Provision | - | -105.00M | -43.00M | -26.00M | 112.00M |
| Net Income | - | -950.00M | -132.00M | -910.00M | -598.00M |
| Diluted EPS | - | -4.41 | -0.62 | -4.48 | -3.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 7.64B | 7.37B | 5.75B | 5.43B |
| Current Assets | - | 1.89B | 1.97B | 1.75B | 2.02B |
| Cash & Equivalents | - | 365.00M | 334.00M | 272.00M | 326.00M |
| Inventory | - | 627.00M | 624.00M | 564.00M | 642.00M |
| Receivables | - | 632.00M | 695.00M | 556.00M | 688.00M |
| Total Liabilities | - | 3.83B | 4.08B | 3.81B | 4.09B |
| Current Liabilities | - | 1.17B | 1.43B | 1.59B | 1.34B |
| Long Term Debt | - | 1.83B | 1.80B | 1.59B | 2.02B |
| Total Debt | - | 2.15B | 2.30B | 2.27B | 2.47B |
| Total Equity | - | 3.81B | 3.29B | 1.94B | 1.34B |
| Shares Outstanding | - | 264.60M | 264.50M | 264.50M | 264.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 517.00M | 377.00M | 461.00M | 235.00M |
| Investing Cash Flow | - | -138.00M | -89.00M | -197.00M | -132.00M |
| Financing Cash Flow | - | -329.00M | -307.00M | -302.00M | -80.00M |
| Capital Expenditure | - | -149.00M | -149.00M | -180.00M | -131.00M |
| Free Cash Flow | - | 368.00M | 228.00M | 281.00M | 104.00M |
| Net Change in Cash | - | 50.00M | -19.00M | -38.00M | 23.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 54.2% | 52.6% | 51.6% | 50.0% |
| Operating Margin % | - | 9.3% | 7.3% | 5.0% | 6.8% |
| Net Margin % | - | -24.2% | -3.3% | -24.0% | -16.2% |
| ROE % | - | -24.9% | -4.0% | -46.9% | -44.7% |
| ROCE % | - | 5.6% | 4.9% | 4.5% | 6.2% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XRAY
XRAY — Frequently Asked Questions
What is the current share price of XRAY?
As of 2026-08-02 19:16 PDT, XRAY trades at $13.37 on NASDAQ/NYSE. Its 52-week range is $9.64 to $14.68.
What is the market capitalisation of XRAY?
XRAY has a market capitalisation of $3.54B on NASDAQ/NYSE.
What is the P/E ratio of XRAY?
XRAY trades at a trailing price-to-earnings (P/E) ratio of -4.46. Its price-to-book (P/B) ratio is 2.64.
What is the return on equity (ROE) of XRAY?
XRAY has a return on equity (ROE) of -44.66%. Its return on capital employed (ROCE) is -9.74%.
Is XRAY a good stock to buy?
This page provides a data-driven analysis of XRAY, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.